Comprehensive analysis of real-world data on liraglutide treatment in patients with obesity: a multicenter national study.

IF 3.4 3区医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL

European Journal of Medical Research Pub Date : 2025-10-10 DOI:10.1186/s40001-025-02836-5

Sema Hepşen, Cem Haymana, Burçak Cavnar Helvacı, Halil Durantaş, Bora Toros, Ramazan Çakmak, Mehmet Güven, İbrahim Demirci, Lezan Keskin, Sinem Kıyıcı, Zehra Yağmur Şahin Alak, Mehmet Sargın, Gonca Tamer, Damla Balcı, Berna İmge Aydoğan, Arzu Or Koca, Mustafa Aydemir, İlhan Tarkun, Pınar Köksal, Ayten Oğuz, Eda Demir Önal, Süleyman Baldane, Muhammed Kızılgül, Erman Çakal, Bekir Çakır, Şefika Burçak Polat, İlhan Yetkin, Emre Bozkırlı, Gülsüm Karaahmetli, Sevgül Fakı, Narimana Imanova Yaghji, Ayşin Öge, Burak Özbaş, Şenay Topsakal, Sevde Nur Fırat, Hayri Bostan, Barış Karagün, Okan Sefa Bakıner, Ayşe Kargılı Çarlıoğlu, Bahri Evren, Kader Uğur, Faruk Kılınç, Adnan Batman, Selin Çakmak Demir, Dilek Yazıcı, Oğuzhan Deyneli, Metin Arslan, Omercan Topaloğlu, Kübra Kocatepe, Kemal Karagözoğlu, Sakin Tekin, Taner Bayraktaroğlu, Sibel Ertek Yalçın, Ayşe Kubat Üzüm, Gökçem Yalın Kocamaz, Mehtap Şahin, Yusuf Aydın, Mustafa Kutlu, Tevfik Sabuncu, Mustafa Cesur, Volkan Demirhan Yumuk, Fahri Bayram, Alper Sönmez

{"title":"Comprehensive analysis of real-world data on liraglutide treatment in patients with obesity: a multicenter national study.","authors":"Sema Hepşen, Cem Haymana, Burçak Cavnar Helvacı, Halil Durantaş, Bora Toros, Ramazan Çakmak, Mehmet Güven, İbrahim Demirci, Lezan Keskin, Sinem Kıyıcı, Zehra Yağmur Şahin Alak, Mehmet Sargın, Gonca Tamer, Damla Balcı, Berna İmge Aydoğan, Arzu Or Koca, Mustafa Aydemir, İlhan Tarkun, Pınar Köksal, Ayten Oğuz, Eda Demir Önal, Süleyman Baldane, Muhammed Kızılgül, Erman Çakal, Bekir Çakır, Şefika Burçak Polat, İlhan Yetkin, Emre Bozkırlı, Gülsüm Karaahmetli, Sevgül Fakı, Narimana Imanova Yaghji, Ayşin Öge, Burak Özbaş, Şenay Topsakal, Sevde Nur Fırat, Hayri Bostan, Barış Karagün, Okan Sefa Bakıner, Ayşe Kargılı Çarlıoğlu, Bahri Evren, Kader Uğur, Faruk Kılınç, Adnan Batman, Selin Çakmak Demir, Dilek Yazıcı, Oğuzhan Deyneli, Metin Arslan, Omercan Topaloğlu, Kübra Kocatepe, Kemal Karagözoğlu, Sakin Tekin, Taner Bayraktaroğlu, Sibel Ertek Yalçın, Ayşe Kubat Üzüm, Gökçem Yalın Kocamaz, Mehtap Şahin, Yusuf Aydın, Mustafa Kutlu, Tevfik Sabuncu, Mustafa Cesur, Volkan Demirhan Yumuk, Fahri Bayram, Alper Sönmez","doi":"10.1186/s40001-025-02836-5","DOIUrl":null,"url":null,"abstract":"Background: The study aimed to evaluate real-world data on liraglutide by assessing its efficacy, associated side effects, adverse events, and impact on metabolic parameters within the context of a multicenter national study.Methods: This retrospective observational study analyzed data from 1009 patients across 38 endocrinology units from Türkiye. Patients with a history of bariatric surgery, those who started orlistat concurrently with liraglutide, and one patient who developed pancreatitis on the 15th day of treatment were excluded from the analyses of weight and laboratory changes.Results: At least one side effect was observed in 48% of the patients, with nausea and vomiting being the most common. The most frequent reason for discontinuing treatment was the cost of the medication (42.6%). The median duration of liraglutide use was 4 months (IQR; 3-6), and the median dose was 2.4 mg (IQR; 1.8-3). Among the entire cohort, 76.4% and 40.9% of patients achieved a 5% and 10% weight loss target, respectively. Significant reductions were observed in metabolic parameters during the treatment. The treatment duration was identified as an independent predictor for achieving 5% and 10% weight loss targets (B = 0.315, p < 0.001) and 10% weight loss (B = 0.216, p < 0.001).Conclusions: Liraglutide effectively results in clinically significant weight loss, achieves expected weight loss targets, and improves metabolic parameters in real-world clinical practice. Therefore, liraglutide is still a reasonable GLP-1 analogue in the obesity treatment. However, it may be associated with various side effects, necessitating close monitoring by clinicians.","PeriodicalId":11949,"journal":{"name":"European Journal of Medical Research","volume":"30 1","pages":"956"},"PeriodicalIF":3.4000,"publicationDate":"2025-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12512425/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Medical Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s40001-025-02836-5","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The study aimed to evaluate real-world data on liraglutide by assessing its efficacy, associated side effects, adverse events, and impact on metabolic parameters within the context of a multicenter national study.

Methods: This retrospective observational study analyzed data from 1009 patients across 38 endocrinology units from Türkiye. Patients with a history of bariatric surgery, those who started orlistat concurrently with liraglutide, and one patient who developed pancreatitis on the 15th day of treatment were excluded from the analyses of weight and laboratory changes.

Results: At least one side effect was observed in 48% of the patients, with nausea and vomiting being the most common. The most frequent reason for discontinuing treatment was the cost of the medication (42.6%). The median duration of liraglutide use was 4 months (IQR; 3-6), and the median dose was 2.4 mg (IQR; 1.8-3). Among the entire cohort, 76.4% and 40.9% of patients achieved a 5% and 10% weight loss target, respectively. Significant reductions were observed in metabolic parameters during the treatment. The treatment duration was identified as an independent predictor for achieving 5% and 10% weight loss targets (B = 0.315, p < 0.001) and 10% weight loss (B = 0.216, p < 0.001).

Conclusions: Liraglutide effectively results in clinically significant weight loss, achieves expected weight loss targets, and improves metabolic parameters in real-world clinical practice. Therefore, liraglutide is still a reasonable GLP-1 analogue in the obesity treatment. However, it may be associated with various side effects, necessitating close monitoring by clinicians.

Abstract Image

查看原文本刊更多论文

利拉鲁肽治疗肥胖患者的实际数据综合分析：一项多中心国家研究。

背景：该研究旨在通过评估利拉鲁肽的疗效、相关副作用、不良事件和对代谢参数的影响，在一项多中心国家研究的背景下评估利拉鲁肽的真实数据。方法：这项回顾性观察性研究分析了来自 rkiye医院38个内分泌科室的1009名患者的数据。有减肥手术史的患者，奥利司他与利拉鲁肽同时开始治疗的患者，以及一名在治疗第15天出现胰腺炎的患者被排除在体重和实验室变化分析之外。结果：48%的患者至少有一种副作用，以恶心和呕吐最为常见。停止治疗最常见的原因是药物费用（42.6%）。利拉鲁肽使用的中位持续时间为4个月（IQR; 3-6），中位剂量为2.4 mg （IQR; 1.8-3）。在整个队列中，76.4%和40.9%的患者分别达到了5%和10%的体重减轻目标。在治疗期间，代谢参数显著降低。治疗时间是实现5%和10%体重减轻目标的独立预测指标（B = 0.315, p）。结论：利拉鲁肽可有效实现临床显著的体重减轻，达到预期的体重减轻目标，并改善现实临床实践中的代谢参数。因此，利拉鲁肽仍是肥胖治疗中合理的GLP-1类似物。然而，它可能与各种副作用有关，需要临床医生密切监测。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European Journal of Medical Research 医学-医学：研究与实验

CiteScore

3.20

自引率

0.00%

发文量

247

审稿时长

>12 weeks

期刊介绍： European Journal of Medical Research publishes translational and clinical research of international interest across all medical disciplines, enabling clinicians and other researchers to learn about developments and innovations within these disciplines and across the boundaries between disciplines. The journal publishes high quality research and reviews and aims to ensure that the results of all well-conducted research are published, regardless of their outcome.